🔭 We propose a biomarker-driven clinical trial model:
• Stratify by CTC count + phenotype
• Adjust treatment intensity
• Monitor CTCs/ctDNA longitudinally
• Assess outcomes in molecular context

🧪 This approach supports personalized strategies beyond conventional clinical or imaging criteria.

❓ Why does this matter?
CTC dynamics can guide treatment intensity—e.g. STIC CTC trial—and integrate with ctDNA to refine therapeutic strategies.
#LiquidBiopsy #OncologyResearch

Mapping Breast Cancer Therapy with Circulating Tumor Cells: the expert perspective Circulating tumor cells (CTCs) have emerged as a key prognostic biomarker for breast cancer, with their role becoming more pronounced in metastatic cases. In metastatic breast cancer, having five or m...

🧵 Thread — Clinical opportunities of circulating tumor cells (CTCs) in breast cancer.

CTCs = validated prognostic marker in MBC:
🏎️ ≥5 CTCs/7.5 mL → stage IVaggressive
🚲 <5 CTCs/7.5 mL → stage IVindolent

Our takeaway 👉 www.thebreastonline.com/article/S096...
#CTCs #BreastCancer

🏁 Our program on cellular residual disease in triple negative breast cancer is about to launch!

Detecting circulating tumor cells in early #TNBC will provide deeper insights into the metastatic process and #immunotherapy response

#BreastCancer #LiquidBiopsy #CTC #PrecisionMedicine

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): mechanisms of resistance and where to find them CDK4/6 inhibitors (CDK4/6i) have significantly impacted on the treatment of HR+ HER2 negative (HER2-) metastatic breast cancer (BC) when combined with…

CDK4/6 inhibitors: mechanisms of resistance and where to find them.
An outside of the box review

Main takeaways:
🛑RB1 loss in #ctDNA predicts poorer PFS
⚠️CCNE1 gain impacts PALOMA-3 outcomes
🧩Role of ESR1 still unclear

Read more👇
www.sciencedirect.com/science/arti...

#bcsm #BreastCancer

Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer - npj Breast Cancer npj Breast Cancer - Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer

Our latest analysis of the GIM14 study identifies clinico-pathological predictors of radiologic complete response (rCR) in HER2+ metastatic #breastcancer:

🌡️ HER2 IHC 3+
🩻 Non-visceral metastases
🎯 Single metastatic site

These data set the stage for the GIM36/INSPIRE1 #liquidbiopsy #MRD trial #bcsm

Intriguing data presented by @lfoffano.bsky.social at the #SABCS24 poster session on how #ctDNA can be leveraged to enhance disease monitoring in metastatic #BreastCancer.

Paving the way to a new #liquidbiopsy informed RECIST

#PrecisionMedicine #bcsm

#EMBER3 takeaways:

imlunestrant 🔼 PFS in patients with #ESR1 mut #MBC (5.5 vs. 3.8 mo)

Combination with abemaciclib further 🔼 PFS regardless of ESR1 and PIK3CA #ctDNA status (9.4 vs. 5.5 mo)

Previous CDK4/6i were mainly Palbo and Ribo in the MBC setting

#SABCS24 #bcsm #BreastCancer

Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial - Nature Communications The clinical implications of molecular heterogeneity in HER2-positive breast cancer remain to be explored. Here, the authors investigate the transcriptomic landscape of HER2-positive breast cancer pat...

Gene profiling performed in the ALTTO trial reveals 5 subtypes within HER2+ #breastcancer, each with distinct prognostic and predictive implications.

Immune-enriched #tumors show the best survival. #bcsm #biomarker #precisonmedicine

www.nature.com/articles/s41...

As more of our researchers and partner organisations join Bluesky, we're creating a #StarterPack to help new users find our connections

If you're in our Institute, work with us or support @cancerresearchuk.bsky.social let us know if you'd like to be added:
go.bsky.app/7PCUW5A

#CRUK #CancerResearch

ISLB Global Survey: Oncologist Attitudes and Practices on Liquid Biopsy About the survey This survey aims to evaluate oncologists' attitudes, practices, and barriers to the use of liquid biopsy in clinical care. Your participation in this survey is voluntary. The survey ...

#ISLB is conducting a global survey on the use of #LiquidBiopsy to uncover current and emerging challenges worldwide.

Your input is crucial to identify key opportunities and issues in our daily practice and share them with stakeholders and the scientific community.

Join us 👇

Awesome day here in Udine for the #TelethonUdine marathon!

This year is an #Oncology and #Genetics joint venture 🏃‍♀️🏃

#UniudRunsForResearch #CroAviano

Collaboration and innovation at #ISLB24! Connecting with brilliant minds to advance the field of #LiquidBiopsy and #PrecisionMedicine. Together, we push boundaries.
@oncoalert.bsky.social
@christianrolfo.bsky.social

Integrating Machine Learning-Predicted Circulating Tumor Cells (CTCs) and circulating tumor DNA (ctDNA) in Metastatic Breast Cancer: a proof of principle study on endocrine resistance profiling The study explored endocrine resistance by leveraging machine learning to establish the prognostic stratification of predicted Circulating tumor cells…

Circulating #tumor cells are a promising proxy #biomarker for endocrine #resistance, an emerging propriety deriving from mulitomic alterations.

👉 Here we explore this concept through a combined 🖥️ in-silico and 🧬 in-vivo approach. #liquidbiopsy #bcsm #oncSky #CTC #ctDNA #breastcancer #MBC